ISPC

iSpecimen Inc. (ISPC) | Rumor.io

iSpecimen

ISPC

Attention (50-day avg)0%

Attention rank (50-day avg)#1,123

Bullish sentiment (50-day avg)82%

Price to earnings ratio-0.01

Market capitalization3M

Earnings per share-50.5

Dividend yield (TTM)—

Revenue (annual)1.9M

Net income (annual)-10.5M

Social

What share of all stock conversation is about ISPC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 24

The price of ISPC after the closing bell was $1.52, representing a 21.60% increase.
The resistance level of $1.65 was broken, and the support level of $1.50 was re-established.
The stock's target prices have been revised to $1.80 and $2.00, with the stop-loss point set at $1.48.

Generated by AI

Sentiment

Of the messages about ISPC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	91.45% +23.05	77.86% +4.82
Bearish	—	0%	8.55% -23.05	22.14% -4.82

Bullish· Aug 21

iSpecimen Inc. ($ISPC) has demonstrated strong operational capabilities by completing a large-scale international cancer research order with hundreds of specimens sourced and shipped within 3 weeks, showcasing real execution rather than just talk.
The stock's 52-week low near the current price presents a potential buying opportunity, with some analysts predicting a push towards $2.50 or higher.
With its biopharma segment gaining traction, $ISPC is seen as a promising investment opportunity, with one analyst predicting a $20 valuation in the future.

Bearish· Aug 20

$ISPC has been heavily shorted, with one user reporting a profit of $7K on a short position.
The market is being manipulated by "fake bulls" who are shorting and selling while telling others to buy, creating a bearish environment.
iSpecimen Inc. has been the subject of a "well orchestrated pump and dump," resulting in significant price drops.

Generated by AI

Topics

Of the messages about ISPC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	52.05%	52.09%
Technical Analysis	—	—	47.95%	46.97%
Analysts	—	—	0%	0.54%
Controversies	—	—	0%	0.13%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.27%

Announcements· May 27

iSpecimen Inc. (ISPC) has completed a $2.5 million private placement with 5.0 months of cash left, estimated current cash of $5.7M, and has done a month reverse stock split.
The company has a low float of 800k and is positioned perfectly with the raging Bundibugyo Ebola crisis, with iSpecimen Inc. being a biospecimen low float catalyst.
E.F. Hutton has served as the exclusive placement agent on iSpecimen Inc.'s $2.5 million private placement, and has also recently served other companies such as HCW Biologics Inc. and XORTX Therapeutics Inc.

Technical Analysis· Mar 13

$ISPC has seen over 16x relative volume and over 4x float rotation, making it a top watch for the morning.
The stock needs to stay above the VWAP and break the new pennant to continue its upward momentum.
$ISPC has formed a potential golden cross and is breaking VWAP, with momentum building and buyers in control, suggesting the trend could have more room to push higher.

Generated by AI

Community

Of the messages about ISPC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	26.67%	44.8%	29.47%
Newcomers	—	73.33%	55.2%	70.53%

Regulars· Sep 8

The regulars are predicting a short squeeze with a potential target of $50, citing the company's unique ecosystem and massive short squeeze potential.
The acquisition and integration of Foldlab's AI is seen as a game-changer, with the potential to increase the company's value by 30-40 times.
The regulars believe that the company's biotech solution is unique and a game-changer in the industry, with the potential to cut drug discovery time down to seconds.

Newcomers· Sep 8

Newcomers are focused on the stock's potential to move over $2.10, with some predicting a big increase.
The stock's recent price action is being closely watched, with one post noting a strong 35% move after running from $1.79 to a high near $2.20.
Some newcomers are bullish on the stock's long-term potential, with targets ranging from $3.50 to $5 and predictions of double-digit returns.

Generated by AI

News

iSpecimen Granted Nasdaq Extension to Regain Compliance

Detailed price information for Ispecimen Inc (ISPC-Q) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

21d agoBenzinga

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

22d agoBenzinga

12 Health Care Stocks Moving In Friday's After-Market Session

25d agoBenzinga

iSpecimen completes cancer research project in three weeks

1mo agoInvesting.com

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

Woburn, MA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- iSpecimen, a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of...

1mo agoBarchart.com

Also Discussed

Investors talking about ISPC also mention

#	Name	Attention
1	Longeveron Inc. Class A Common StockLGVN	0%0
2	Biofrontera Inc.BFRI	0%0
3	PTPI - Petros Pharmaceuticals, Inc.	——
4	Pasithea Therapeutics Corp.KTTA	0%0
5	Society Pass IncorporatedSOPA	0%0
6	Ensysce Biosciences, Inc. Common StockENSC	0%0
7	Local Bounti CorporationLOCL	0%0
8	Context Therapeutics Inc.CNTX	0%0
9	Cumberland Pharmaceuticals Inc.CPIX	0%new
10	Immix Biopharma, Inc.IMMX	0.03%+0.03

iSpecimen Inc.

Healthcare
Diagnostics & Research

iSpecimen Inc. is a technology-driven life sciences company that operates an online marketplace for human biospecimens and associated clinical data. The company connects researchers in industry, academia, and government with healthcare providers that supply biofluids, tissues, living cells, and other specimens needed for medical research. Its platform centralizes the sourcing, search, contracting, and compliance process, helping buyers access a broad network of providers through a single digital workflow. iSpecimen Inc. serves the biomedical research market by supporting studies in drug development, diagnostics, and translational medicine. Headquartered in Woburn, Massachusetts, iSpecimen Inc. focuses on improving the efficiency of biospecimen procurement and expanding access to research materials across global life science markets.

Website

Location

8 Cabot Road

Woburn, MA, 01801

United States

Social

What share of all stock conversation is about ISPC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 24

The price of ISPC after the closing bell was $1.52, representing a 21.60% increase.
The resistance level of $1.65 was broken, and the support level of $1.50 was re-established.
The stock's target prices have been revised to $1.80 and $2.00, with the stop-loss point set at $1.48.

Generated by AI

Sentiment

Of the messages about ISPC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	91.45% +23.05	77.86% +4.82
Bearish	—	0%	8.55% -23.05	22.14% -4.82

Bullish· Aug 21

iSpecimen Inc. ($ISPC) has demonstrated strong operational capabilities by completing a large-scale international cancer research order with hundreds of specimens sourced and shipped within 3 weeks, showcasing real execution rather than just talk.
The stock's 52-week low near the current price presents a potential buying opportunity, with some analysts predicting a push towards $2.50 or higher.
With its biopharma segment gaining traction, $ISPC is seen as a promising investment opportunity, with one analyst predicting a $20 valuation in the future.

Bearish· Aug 20

$ISPC has been heavily shorted, with one user reporting a profit of $7K on a short position.
The market is being manipulated by "fake bulls" who are shorting and selling while telling others to buy, creating a bearish environment.
iSpecimen Inc. has been the subject of a "well orchestrated pump and dump," resulting in significant price drops.

Generated by AI

Topics

Of the messages about ISPC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	52.05%	52.09%
Technical Analysis	—	—	47.95%	46.97%
Analysts	—	—	0%	0.54%
Controversies	—	—	0%	0.13%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.27%

Announcements· May 27

iSpecimen Inc. (ISPC) has completed a $2.5 million private placement with 5.0 months of cash left, estimated current cash of $5.7M, and has done a month reverse stock split.
The company has a low float of 800k and is positioned perfectly with the raging Bundibugyo Ebola crisis, with iSpecimen Inc. being a biospecimen low float catalyst.
E.F. Hutton has served as the exclusive placement agent on iSpecimen Inc.'s $2.5 million private placement, and has also recently served other companies such as HCW Biologics Inc. and XORTX Therapeutics Inc.

Technical Analysis· Mar 13

$ISPC has seen over 16x relative volume and over 4x float rotation, making it a top watch for the morning.
The stock needs to stay above the VWAP and break the new pennant to continue its upward momentum.
$ISPC has formed a potential golden cross and is breaking VWAP, with momentum building and buyers in control, suggesting the trend could have more room to push higher.

Generated by AI

Community

Of the messages about ISPC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	26.67%	44.8%	29.47%
Newcomers	—	73.33%	55.2%	70.53%

Regulars· Sep 8

The regulars are predicting a short squeeze with a potential target of $50, citing the company's unique ecosystem and massive short squeeze potential.
The acquisition and integration of Foldlab's AI is seen as a game-changer, with the potential to increase the company's value by 30-40 times.
The regulars believe that the company's biotech solution is unique and a game-changer in the industry, with the potential to cut drug discovery time down to seconds.

Newcomers· Sep 8

Newcomers are focused on the stock's potential to move over $2.10, with some predicting a big increase.
The stock's recent price action is being closely watched, with one post noting a strong 35% move after running from $1.79 to a high near $2.20.
Some newcomers are bullish on the stock's long-term potential, with targets ranging from $3.50 to $5 and predictions of double-digit returns.

Generated by AI

iSpecimen

Social

Sep 24

Bullish· Aug 21

Bearish· Aug 20

Announcements· May 27

Technical Analysis· Mar 13

Regulars· Sep 8

Newcomers· Sep 8

iSpecimen Granted Nasdaq Extension to Regain Compliance

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Friday's After-Market Session

iSpecimen completes cancer research project in three weeks

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

Also Discussed

iSpecimen Inc.

Company Information

Location

iSpecimen Granted Nasdaq Extension to Regain Compliance

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Friday's After-Market Session

iSpecimen completes cancer research project in three weeks

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

Also Discussed

Social

Sep 24

Bullish· Aug 21

Bearish· Aug 20

Announcements· May 27

Technical Analysis· Mar 13

Regulars· Sep 8

Newcomers· Sep 8